Maria Aaanesland Dahle

  • PhD candidate; MSc
  • 22781861
 

Publications 2026

Pladsen AV, Smebye ML, Garred Ø, Borgen E, Egeland EV, Haugen MH, Dahle MA, Prasmickaite L, Mælandsmo GM, Hovig E, Nakken S, Østgaard A, Bergheim IR, Reinertsen K, Ohnstad HO, Schlichting E, Skjerven HK, Dale AB, Wist E, Naume B, Russnes HG, Lingjærde OC, Engebraaten O (2026)
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer
Clin Cancer Res (in press)
DOI 10.1158/1078-0432.CCR-26-2212, PubMed 42870529

Publications 2025

Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O (2025)
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy
Breast Cancer Res, 27 (1), 143
DOI 10.1186/s13058-025-02092-9, PubMed 40790765

Publications 2024

Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L (2024)
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
Br J Cancer, 131 (10), 1656-1667
DOI 10.1038/s41416-024-02875-5, PubMed 39390250

Publications 2023

Liu T, Dahle MA, Lystad MH, Marignol L, Karlsen M, Redalen KR (2023)
In vitro and in vivo characterization of [64Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors
Eur J Nucl Med Mol Imaging, 50 (12), 3576-3588
DOI 10.1007/s00259-023-06310-4, PubMed 37382663